CORONA Remedies Q3 FY26 Revenue Up 15% to ₹342.42 Cr, PAT Rises 23.7%
CORONA Remedies reported Q3 FY26 consolidated revenue of ₹342.42 Cr, up 15.0% YoY, and PAT of ₹55.56 Cr, up 23.7% YoY. Nine-month FY26 revenue reached ₹1050.09 Cr (up 16.3% YoY) and PAT was ₹154.08 Cr (up 30.7% YoY). MD & CEO Nirav K. Mehta noted consistent growth and outperformance.
The announcement details significant financial performance with substantial growth in revenue and profit, along with positive commentary from the MD & CEO, which is likely to be viewed favorably by investors.
The company reported strong year-on-year growth in both revenue and profit after tax for the quarter and nine months, exceeding its guided targets. Management commentary also reflects positive outlook and successful execution of strategy.
CORONA Remedies Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue from operations of ₹342.42 crore for Q3 FY26, marking a 15.0% year-on-year growth. For the nine months of FY26, the revenue stood at ₹1050.09 crore, an increase of 16.3% YoY.
Profit After Tax (PAT) for the third quarter of FY26 was ₹55.56 crore, reflecting a 23.7% YoY growth. The PAT for the nine months of FY26 reached ₹154.08 crore, up by 30.7% YoY. These figures exclude a one-time statutory impact of ₹19.10 crore (post-tax ₹14.29 crore) related to the New Labour Code.
The company's EBITDA for Q3 FY26 was ₹83.16 crore, with an EBITDA margin of 24.3%. For the nine months FY26, EBITDA was ₹231.42 crore with a margin of 22.0%. Key financial metrics for the nine months FY26 include a Return on Equity (RoE) of 31.1% and Return on Capital Employed (RoCE) of 48.0% (annualized). The company also maintained a healthy Net Working Capital Days of 18 days.
Mr. Nirav K. Mehta, Managing Director and CEO, expressed delight with the strong financial performance, highlighting that the company has consistently met its aspirations of growing revenue by 15% and PAT by 20%. He attributed the success to a consistent strategy, disciplined execution, and a focus on core therapeutic segments, including strengthening the field force and expanding the brand portfolio.
CORONA Remedies Limited will host an earnings call on February 03, 2026, at 4:00 PM IST to discuss the financial and business performance.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.